Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36.25 GBX | 0.00% | +4.32% | -21.20% |
Apr. 24 | ActiveOps sales up; Sancus turnover jumps | AN |
Mar. 01 | EARNINGS AND TRADING: Dar Global celebrates "outstanding" year | AN |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's enterprise value to sales, at 3.26 times its current sales, is high.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.20% | 157M | - | ||
+73.17% | 12.38B | B- | ||
-18.74% | 7.92B | C+ | ||
+16.15% | 7.2B | C- | ||
+4.81% | 5.84B | B | ||
+5.99% | 5.07B | D+ | ||
+27.07% | 4.53B | - | ||
-21.67% | 3.88B | B- | ||
-40.82% | 2.23B | C | ||
+1.49% | 2.02B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CREO Stock
- Ratings Creo Medical Group PLC